- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7799
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Tips for erythropoiesis-stimulating agent treatment of renal anemia ; volume:24 ; number:1 ; day:16 ; month:10 ; year:2019 ; pages:105-106 ; date:1.2020
Clinical and experimental nephrology ; 24, Heft 1 (16.10.2019), 105-106, 1.2020
- Creator
-
Tomosugi, Naohisa
Koshino, Yoshitaka
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10157-019-01791-w
- URN
-
urn:nbn:de:101:1-2020041402581015182797
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tomosugi, Naohisa
- Koshino, Yoshitaka
- SpringerLink (Online service)
Other Objects (12)
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy
Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis
Erythroid-intrinsic activation of TLR8 impairs erythropoiesis in inherited anemia
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy
Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis
Erythroid-intrinsic activation of TLR8 impairs erythropoiesis in inherited anemia
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy
Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis
Erythroid-intrinsic activation of TLR8 impairs erythropoiesis in inherited anemia
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient